Eye med Eylea has been a blockbuster sales force for Regeneron, but Novartis’ challenger brolucizumab is on the horizon. Could a new delivery option give Eylea a leg up?
That’s what Regeneron’s hoping. The FDA Tuesday approved a new pre-filled injector for 2-milligram single doses of Eylea to treat patients with wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy.
The drugmaker touted the new approval as a game-changer for physicians, taking multiple preparation steps out of the original vial dose regimen. Eylea is now the only drug approved to treat four retinal diseases with a pre-filled injector, and the newest green light should help it secure its place as the top-performing wet AMD drug on the market as competitors loom.
Novartis’ brolucizumab, a wannabe rival in wet AMD, is under priority review from the FDA, and it could steal the limelight from Eylea and its only approved competitor, Roche’s Lucentis. Novartis’ drug boasts strong head-to-head data against Eylea, including wins against the older drug in reducing retinal fluid and central subfield thickness.
But Regeneron hasn’t taken that challenge sitting down. In May, Eylea received an FDA nod to treat all forms of diabetic retinopathy, a condition that affects about 8 million people worldwide and is the leading cause of blindness in U.S. adults, the company said.
That new indication helped drive Eylea sales up 17% in the second quarter to $1.16 billion. Those sales represent a significant chunk of the drugmaker’s total $1.9 billion in the quarter.
It also followed positive results from the drug’s phase 3 trial dubbed Panorama, which showed an 85% and 88% risk reduction for diabetic retinopathy patients developing proliferative diabetic retinopathy (PDR) at the one-year mark when dosing every 16 and eight weeks, respectively. Twenty percent of untreated patients developed PDR, which causes abnormal blood vessel growth on retinas and potentially vision loss, at the one-year mark, the company said.
Strong sales have been a boon for Regeneron as another pillar of its growth strategy—an antibody partnership with Sanofi on PCSK9 inhibitor Praluent and Dupixent—is just now turning a profit.
Fueled by Dupixent’s $557 million in second-quarter sales—a 166% increase—Regeneron last week reported that its Sanofi partnership posted a $39 million profit, a big turnabout from the same period last year, when it cost Regeneron $69 million.
By: Kyle Blankenship
Source: Fierce Pharma
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
